Coverage
-
September 04, 2020
Cocrystal Pharma Inc. will implement a series of corporate reforms to settle three derivative suits brought by shareholders over an alleged $27 million pump-and-dump scheme that drove down the value of the company's stock, according to a motion Friday in New Jersey federal court seeking preliminary approval of the deal.
2 other articles on this case.
View all »